GEORGE CHOLANKERIL to Cost-Benefit Analysis
This is a "connection" page, showing publications GEORGE CHOLANKERIL has written about Cost-Benefit Analysis.
Connection Strength
0.054
-
Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates. World J Gastroenterol. 2018 Jan 21; 24(3):315-322.
Score: 0.028
-
Treatment of patients waitlisted for liver transplant with all-oral direct-acting antivirals is a cost-effective treatment strategy in the United States. Hepatology. 2017 07; 66(1):46-56.
Score: 0.026